Fintel reports that on May 23, 2023, Goldman Sachs upgraded their outlook for Myriad Genetics (NASDAQ:MYGN) from Sell to Buy.
Analyst Price Forecast Suggests 9.55% Upside
As of May 11, 2023, the average one-year price target for Myriad Genetics is 21.99. The forecasts range from a low of 13.13 to a high of $31.50. The average price target represents an increase of 9.55% from its latest reported closing price of 20.07.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Myriad Genetics is 743MM, an increase of 6.94%. The projected annual non-GAAP EPS is -0.12.
What is the Fund Sentiment?
There are 449 funds or institutions reporting positions in Myriad Genetics. This is a decrease of 9 owner(s) or 1.97% in the last quarter. Average portfolio weight of all funds dedicated to MYGN is 0.12%, an increase of 2.89%. Total shares owned by institutions increased in the last three months by 0.26% to 90,142K shares. The put/call ratio of MYGN is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
Camber Capital Management holds 7,000K shares representing 8.58% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 6,731K shares representing 8.25% ownership of the company. In it’s prior filing, the firm reported owning 6,787K shares, representing a decrease of 0.84%. The firm decreased its portfolio allocation in MYGN by 77.85% over the last quarter.
IJR – iShares Core S&P Small-Cap ETF holds 6,023K shares representing 7.39% ownership of the company. In it’s prior filing, the firm reported owning 5,910K shares, representing an increase of 1.88%. The firm decreased its portfolio allocation in MYGN by 29.49% over the last quarter.
Glenview Capital Management holds 4,195K shares representing 5.14% ownership of the company. In it’s prior filing, the firm reported owning 3,098K shares, representing an increase of 26.16%. The firm increased its portfolio allocation in MYGN by 114.71% over the last quarter.
VEXPX – VANGUARD EXPLORER FUND Investor Shares holds 3,693K shares representing 4.53% ownership of the company. In it’s prior filing, the firm reported owning 3,121K shares, representing an increase of 15.49%. The firm increased its portfolio allocation in MYGN by 5.69% over the last quarter.
Myriad Genetics Background Information
(This description is provided by the company.)
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
Key filings for this company:
This article originally appeared on Fintel
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
